The integration of next-generation sequencing panels in the clinical cancer genetics practice: An institutional experience

Caitlin B. Mauer, Sara M. Pirzadeh-Miller, Linda D. Robinson, David M Euhus

Research output: Contribution to journalArticle

Abstract

Purpose:The advent of next-generation sequencing for cancer susceptibility genes holds promise for clinical genetics application, but the practical issues surrounding integration of this testing into the clinical setting have not been well addressed. This article describes the clinical experience of genetic counselors in an academic and community setting with next-generation sequencing cancer panels.Methods:Between April 2012 and January 2013, 60 next-generation sequencing panels were ordered. A retrospective review was conducted to determine the indication for ordering the results of the tests and the patient management based on the results.Results:Ten tests were canceled due to out-of-pocket costs or previously identified mutations. Among the 50 tests, 5 (10%) showed a positive result. Moreover, 15 of the 50 (30%) panels detected variant(s) of uncertain significance or variant(s) suspected benign.Conclusion:We propose clinical guidelines for identifying high-risk patients who should be offered this testing. Our data support the National Comprehensive Cancer Network recommendations that next-generation sequencing be ordered as a second-tier test for high-risk individuals with cancer by trained cancer genetics providers. Literature review and expert knowledge should be used to create management plans for the identification of both positive and variants of uncertain significance results. Providers should be aware of limitations regarding reimbursement for testing and recommended management strategies.

Original languageEnglish (US)
Pages (from-to)407-412
Number of pages6
JournalGenetics in Medicine
Volume16
Issue number5
DOIs
StatePublished - 2014
Externally publishedYes

Fingerprint

Institutional Practice
Neoplasms
Neoplasm Genes
Health Expenditures
Guidelines
Mutation

Keywords

  • BRCA
  • genetic testing
  • genomics
  • next-generation sequencing
  • panel testing

ASJC Scopus subject areas

  • Genetics(clinical)
  • Medicine(all)

Cite this

The integration of next-generation sequencing panels in the clinical cancer genetics practice : An institutional experience. / Mauer, Caitlin B.; Pirzadeh-Miller, Sara M.; Robinson, Linda D.; Euhus, David M.

In: Genetics in Medicine, Vol. 16, No. 5, 2014, p. 407-412.

Research output: Contribution to journalArticle

Mauer, Caitlin B. ; Pirzadeh-Miller, Sara M. ; Robinson, Linda D. ; Euhus, David M. / The integration of next-generation sequencing panels in the clinical cancer genetics practice : An institutional experience. In: Genetics in Medicine. 2014 ; Vol. 16, No. 5. pp. 407-412.
@article{904a690a8708433781ecc993d868a216,
title = "The integration of next-generation sequencing panels in the clinical cancer genetics practice: An institutional experience",
abstract = "Purpose:The advent of next-generation sequencing for cancer susceptibility genes holds promise for clinical genetics application, but the practical issues surrounding integration of this testing into the clinical setting have not been well addressed. This article describes the clinical experience of genetic counselors in an academic and community setting with next-generation sequencing cancer panels.Methods:Between April 2012 and January 2013, 60 next-generation sequencing panels were ordered. A retrospective review was conducted to determine the indication for ordering the results of the tests and the patient management based on the results.Results:Ten tests were canceled due to out-of-pocket costs or previously identified mutations. Among the 50 tests, 5 (10{\%}) showed a positive result. Moreover, 15 of the 50 (30{\%}) panels detected variant(s) of uncertain significance or variant(s) suspected benign.Conclusion:We propose clinical guidelines for identifying high-risk patients who should be offered this testing. Our data support the National Comprehensive Cancer Network recommendations that next-generation sequencing be ordered as a second-tier test for high-risk individuals with cancer by trained cancer genetics providers. Literature review and expert knowledge should be used to create management plans for the identification of both positive and variants of uncertain significance results. Providers should be aware of limitations regarding reimbursement for testing and recommended management strategies.",
keywords = "BRCA, genetic testing, genomics, next-generation sequencing, panel testing",
author = "Mauer, {Caitlin B.} and Pirzadeh-Miller, {Sara M.} and Robinson, {Linda D.} and Euhus, {David M}",
year = "2014",
doi = "10.1038/gim.2013.160",
language = "English (US)",
volume = "16",
pages = "407--412",
journal = "Genetics in Medicine",
issn = "1098-3600",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - The integration of next-generation sequencing panels in the clinical cancer genetics practice

T2 - An institutional experience

AU - Mauer, Caitlin B.

AU - Pirzadeh-Miller, Sara M.

AU - Robinson, Linda D.

AU - Euhus, David M

PY - 2014

Y1 - 2014

N2 - Purpose:The advent of next-generation sequencing for cancer susceptibility genes holds promise for clinical genetics application, but the practical issues surrounding integration of this testing into the clinical setting have not been well addressed. This article describes the clinical experience of genetic counselors in an academic and community setting with next-generation sequencing cancer panels.Methods:Between April 2012 and January 2013, 60 next-generation sequencing panels were ordered. A retrospective review was conducted to determine the indication for ordering the results of the tests and the patient management based on the results.Results:Ten tests were canceled due to out-of-pocket costs or previously identified mutations. Among the 50 tests, 5 (10%) showed a positive result. Moreover, 15 of the 50 (30%) panels detected variant(s) of uncertain significance or variant(s) suspected benign.Conclusion:We propose clinical guidelines for identifying high-risk patients who should be offered this testing. Our data support the National Comprehensive Cancer Network recommendations that next-generation sequencing be ordered as a second-tier test for high-risk individuals with cancer by trained cancer genetics providers. Literature review and expert knowledge should be used to create management plans for the identification of both positive and variants of uncertain significance results. Providers should be aware of limitations regarding reimbursement for testing and recommended management strategies.

AB - Purpose:The advent of next-generation sequencing for cancer susceptibility genes holds promise for clinical genetics application, but the practical issues surrounding integration of this testing into the clinical setting have not been well addressed. This article describes the clinical experience of genetic counselors in an academic and community setting with next-generation sequencing cancer panels.Methods:Between April 2012 and January 2013, 60 next-generation sequencing panels were ordered. A retrospective review was conducted to determine the indication for ordering the results of the tests and the patient management based on the results.Results:Ten tests were canceled due to out-of-pocket costs or previously identified mutations. Among the 50 tests, 5 (10%) showed a positive result. Moreover, 15 of the 50 (30%) panels detected variant(s) of uncertain significance or variant(s) suspected benign.Conclusion:We propose clinical guidelines for identifying high-risk patients who should be offered this testing. Our data support the National Comprehensive Cancer Network recommendations that next-generation sequencing be ordered as a second-tier test for high-risk individuals with cancer by trained cancer genetics providers. Literature review and expert knowledge should be used to create management plans for the identification of both positive and variants of uncertain significance results. Providers should be aware of limitations regarding reimbursement for testing and recommended management strategies.

KW - BRCA

KW - genetic testing

KW - genomics

KW - next-generation sequencing

KW - panel testing

UR - http://www.scopus.com/inward/record.url?scp=84899974241&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899974241&partnerID=8YFLogxK

U2 - 10.1038/gim.2013.160

DO - 10.1038/gim.2013.160

M3 - Article

C2 - 24113346

AN - SCOPUS:84899974241

VL - 16

SP - 407

EP - 412

JO - Genetics in Medicine

JF - Genetics in Medicine

SN - 1098-3600

IS - 5

ER -